Physician profile
Arvind Suri
NPI 1780856252
$5,856.72
in general payments reported to CMS, 2019-2025
26 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.19 · 2020: $250 · 2021: $672 · 2022: $710 · 2023: $1,144 · 2024: $1,133 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.01 |
| Education | $152.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,692.81 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $775.49 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.97 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $329.99 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $251.20 | 2021-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $211.90 | 2019-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $167.26 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $120.50 | 2021-2022 | |
| Novo Nordisk INC | $115.22 | 2020-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $113.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $76.92 | 2021-2023 | |
| Amgen INC. | $66.09 | 2021-2023 | Otezla, Repatha |
| Eisai INC. | $64.81 | 2021 | |
| Pfizer INC. | $52.63 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $48.24 | 2024-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $23.97 | 2024 | Korlym |
| Medtronic Minimed, INC. | $23.58 | 2020 | |
| Allergan, INC. | $22.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.88 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $21.97 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $20.83 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $20.06 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $19.67 | 2025 | Closurefast |
| Biohaven Pharmaceuticals, INC. | $18.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.71 | 2022 | |
| Merck Sharp & Dohme LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.